Healthcare

Cardiac Troponin Diagnostics—Forecasts and Opportunities to 2025

Demand for High Sensitivity Point-of-Care Testing Enhance Growth Potential

INDUSTRY
Healthcare

RELEASE DATE
16-Nov-2022
REGION
North America
DELIVERABLE TYPE
Market Research

RESEARCH CODE
PDB7-01-00-00-00
SKU
HC03602-NA-MT_27122
Yes
SHARE

Cardiac Troponin Diagnostics—Forecasts and Opportunities to 2025
Published on: 16-Nov-2022 | SKU: HC03602-NA-MT_27122

Need more details?

$4,950.00

$3,712.50 save 25 %

DownloadLink
Need more details?

Cardiac troponin (cTn) biomarkers are the gold standard in myocardial infarction (MI) diagnosis, leading healthcare professionals to use cTn diagnostics. In addition, a rising number of patients visit emergency departments (EDs) with cardiac complaints, increasing ED demand for kits
that can rapidly rule MI in or out. Both factors serve as significant drivers of the cTn diagnostics market.

Hospitals and clinical laboratories adopt high-sensitivity (hs) assays because of their ability to detect troponin in lower concentrations. The point-of-care testing (POCT) of cTn grows rapidly due to its rising applications in EDs and remote locations. POCT can provide rapid results in a shorter period than lab-based tests. In addition, companies such as QuidelOrtho and Siemens Healthineers have developed high-sensitivity POCT cTn assays that provide accurate results within a few minutes.

In this report, Frost & Sullivan overviews the cTn diagnostics market and includes troponin I and troponin T. Our testing locations are independent laboratories, physicians’ offices, urgent care and nursing facilities, inpatient hospitals, and emergency rooms. The study covers sensitive and
hs-cTn tests.

The report also includes the following:
• Market size by revenue, covering historic and forecast data by segment (lab-based tests and POCT) and region (North America, Europe,
Asia-Pacific, and the rest of the world)
• Challenges and drivers
• Competitive landscape, including company market share for lab-based tests and POCT
• Future trends and growth opportunities for stakeholders

North America is the leading region in the cTn diagnostics market, with hospitals and laboratories shifting toward high-sensitivity assays following approval from the United States Food and Drug Administration in 2017. Frost & Sullivan’s research shows high consolidation in the cTn diagnostics market, with players such as Abbot, Roche, and Siemens Healthineers dominating. New players are entering this market, especially in the POCT segment.

Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on the Cardiac Troponin (cTn) Diagnostics Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Cardiac Biomarkers

Timeline for Cardiac Biomarkers for MI

cTns

Clinical Pathway for MI Diagnosis

cTn Diagnostics

cTn Diagnostics (continued)

Scope of Analysis

Segmentation

Competitors

Growth Metrics

Growth Drivers

Growth Restraints

Forecast Assumptions

Revenue Forecast

Revenue Forecast by Product Type

Revenue Forecast by Region

Revenue Forecast Analysis

Revenue Forecast Analysis (continued)

Revenue Forecast Analysis by Region

Competitive Environment

Revenue Share

Revenue Share Analysis

Company Mapping

Companies to Watch

High-sensitivity Troponin Diagnostic—Emerging Applications

New Biomarkers for MI

Growth Metrics

Revenue Forecast

Revenue Forecast by Region

Forecast Analysis

Growth Metrics

Revenue Forecast by Product Type

Revenue Forecast by Region

Forecast Analysis

Growth Opportunity 1: Rapid Diagnostics for EDs

Growth Opportunity 1: Rapid Diagnostics for EDs (continued)

Growth Opportunity 2: hs-cTn POCT

Growth Opportunity 2: hs-cTn POCT (continued)

Growth Opportunity 3: Digital Health and Diagnostics Inter-convergence Model

Growth Opportunity 3: Digital Health and Diagnostics Inter-convergence Model (continued)

Growth Opportunity 4: Specific and Sensitive Assays for Rapid MI Detection

Growth Opportunity 4: Specific and Sensitive Assays for Rapid MI Detection (continued)

Your Next Steps

Why Frost, Why Now?

List of Exhibits

Legal Disclaimer

List of Figures
  • cTn Diagnostics: Growth Metrics, Global, 2021
  • cTn Diagnostics: Growth Drivers, Global, 2022–2025
  • cTn Diagnostics: Growth Restraints, Global, 2022–2025
  • cTn Diagnostics: Revenue Forecast, Global, 2017–2025
  • cTn Diagnostics: Revenue Forecast by Product Type, Global, 2017–2025
  • cTn Diagnostics: Revenue Forecast by Region, 2017–2025
  • cTn Diagnostics: Revenue Share of Top Participants, Global, 2021
  • cTn Diagnostics: Product Comparison by Company, 2022
  • Lab-based Tests: Growth Metrics, Global, 2021
  • Lab-based Tests: Revenue Forecast, Global, 2017–2025
  • Lab-based Tests: Revenue Forecast by Region, Global, 2017–2025
  • POCT: Growth Metrics, Global, 2021
  • POCT: Revenue Forecast, Global, 2017–2025
  • POCT: Revenue Forecast by Region, Global, 2017–2025

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Healthcare research

17 Nov 2026   |   Global   |   Frost Radar

Frost Radar™: Quantum-Grade Sensor Technology Ecosystem for Healthcare Applications, 2026

Quantum-grade sensors are advancing healthcare by leveraging quantum phenomena to enable highly sensitive, precise, and non-invasive measurements of biological signals and physiological parameters. These innovations enhance diagnostic accuracy, disease monitoring, brain activity measurement, and ear...

16 Nov 2026   |   North America   |   Frost Radar

Frost Radar™: Healthcare Data Interoperability Platforms and Integration Engines in North America, 2026

This Frost Radar™ analyzes the healthcare data platform and integration engine vendors that enable healthcare organization to improve the exchange, utilization, contextualization, and management of clinical, operational, financial, and administrative data. Data issues, AI adoption, and solution gove...

03 Nov 2026   |   North America   |   Market Research

Enterprise Imaging Market, United States, 2025–2030

Enterprise imaging is no longer a technology upgrade. It is becoming the operating model for imaging across the provider organization, and the next investment cycle will decide which vendors lead it. This study gives vendors, ecosystem partners, and provider leaders a 360-degree view of that shift, ...

02 Nov 2026   |   Global   |   Market Research

Continuous Glucose Monitoring Market, Global, 2026

The global continuous glucose monitoring (CGM) market is undergoing a fundamental transformation as the technology evolves from a prescription-led glucose monitoring device into an AI-connected metabolic intelligence ecosystem. Market expansion is increasingly driven by the emergence of over-the-cou...

28 Oct 2026   |   Global   |   Frost Radar

Frost Radar™: Health Monitoring Wearable Solutions, 2026

The health monitoring wearables industry is undergoing a profound transformation as competitive advantage shifts from device hardware to integrated digital health ecosystems. Market leaders are differentiating through clinically validated health insights, longitudinal data platforms, AI-enabled anal...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.